With facilities in Boston, MA and in San Francisco, CA., Pear Therapeutics Inc (NASDAQ:PEAR) is a health-care firm promoting use of software applications to treat a person's health: prescription digital therapeutics, or PDTs. With the firm only recently having gone public (Dec 2021) Pear is structured around redefining medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. With an impressive listing of pre-IPO investors, the company is structured around treating substance disorders, schizophrenia, pain, Post-traumatic stress disorder, anxiety, depression, and sleep.The firm is developing PDTs to treat diseases with products such as reSET, reSET-O, Thrive, and reCALL. ReSET is designed to treat those with substance abuse issues, as reSET-O treats opioid disorders. Pear's digital therapies, known as eFormulations, are designed to treat disease and enhance efficacy of already-approved prescription pharmaceuticals with reduced clinician intervention. Pear is organized around developing and commercializing its eFormulations pipeline, which includes reSET for substance use disorder and reSET-O for opioid-use disorder; both potential digital therapies include a patient-facing smartphone application and a clinician-facing web interface and have demonstrated positive results in abstinence and retention in treatment. The firm has an extraordinarily long list of investors (23 total pre- and post IPO) to include high profile, heavy hitters inthe space.
